Vepdegestrant PROTAC ER Degrader FDA Filing — PatSnap Eureka
Vepdegestrant: The First PROTAC ER Degrader Seeking FDA Approval in ESR1-Mutant Breast Cancer
Arvinas and Pfizer's ARV-471 (vepdegestrant) has reached a historic regulatory milestone — the first PROTAC compound ever to seek FDA approval, targeting ESR1-mutant ER+/HER2− metastatic breast cancer with a statistically significant Phase 3 PFS benefit over fulvestrant.
How Vepdegestrant Degrades ERα — Including Constitutively Active ESR1 Mutants
Vepdegestrant (ARV-471) is a bifunctional PROTAC compound comprising an ERα ligand linked to a cereblon (CRBN) E3 ubiquitin ligase ligand via a chemical linker. Unlike selective estrogen receptor modulators (SERMs) or degraders (SERDs) that operate through occupancy-driven receptor antagonism, vepdegestrant operates through event-driven, catalytic pharmacology: the PROTAC molecule bridges CRBN and ERα into a ternary complex, induces polyubiquitination of ERα, and delivers the receptor to the 26S proteasome for degradation — after which the PROTAC is recycled and can engage additional target molecules.
This mechanism is particularly significant for ESR1 ligand-binding domain (LBD) hotspot mutations — specifically Y537S and D538G — which cause constitutive ERα activation independent of estrogen. Structural studies confirm that PROTAC-based protein removal overcomes constitutive activation better than traditional antagonism, because the receptor is eliminated entirely rather than merely blocked. Vepdegestrant achieves >90% ERα reduction in tumour tissue, compared to approximately 60% for elacestrant (oral SERD) and approximately 50% for fulvestrant (injectable SERD) in preclinical ESR1-mutant models.
The CRBN-based E3 ligase recruitment strategy and the catalytic, substoichiometric target engagement represent a fundamentally new pharmacological paradigm — one that the FDA is now evaluating for the first time in a PROTAC NDA submission. Learn more about PatSnap's life sciences intelligence platform for tracking degrader drug development.
The ubiquitin-proteasome system (UPS) has been extensively characterised by NIH-funded research as a viable therapeutic target, and vepdegestrant's NDA represents the first clinical validation of this approach in oncology at the regulatory level.
ERα Degradation Efficacy & ESR1 Mutation Prevalence
Key quantitative data from patent literature and clinical studies underpinning vepdegestrant's regulatory case, analysed via PatSnap Eureka.
ERα Degradation Efficiency by Agent in ESR1-Mutant Models
Vepdegestrant achieves >90% ERα reduction vs. ~60% for elacestrant and ~50% for fulvestrant in ESR1 Y537S/D538G preclinical models.
ESR1 Mutation Prevalence Post-CDK4/6 Inhibitor + AI Therapy
~40% of patients progressing on CDK4/6 inhibitor + aromatase inhibitor combinations develop ESR1 mutations, defining the VERITAC-2 eligible population.
Vepdegestrant Patent Portfolio by Filing Category
The Arvinas/Pfizer IP estate spans composition-of-matter, method-of-use, combination, formulation, and companion diagnostic patents — a layered protection strategy.
Event-Driven vs. Occupancy-Driven Pharmacology
PROTACs operate catalytically — one molecule degrades multiple ERα copies — while SERDs require stoichiometric receptor occupancy to achieve downregulation.
The Clinical & Regulatory Case for the First PROTAC Approval
The VERITAC-2 Phase 3 trial and its NDA submission represent an unprecedented regulatory milestone for targeted protein degradation technology.
Phase 3 vs. Fulvestrant in ESR1-Mutant ER+/HER2− Advanced Breast Cancer
VERITAC-2 is a randomised Phase 3 trial comparing vepdegestrant (200 mg orally once daily) versus fulvestrant in patients with ESR1-mutant ER+/HER2− advanced breast cancer previously treated with a CDK4/6 inhibitor and endocrine therapy. The primary endpoint was progression-free survival (PFS). Vepdegestrant showed a statistically significant improvement in PFS versus fulvestrant in the ESR1-mutant population, forming the basis of the NDA regulatory submission package.
Primary endpoint: PFS — statistically significantCDK4/6 Inhibitor-Pretreated Patients with ESR1 Mutations Detected by ctDNA
The VERITAC-2 eligible population reflects the clinical reality that ESR1 mutations emerge in approximately 40% of patients progressing on CDK4/6 inhibitor plus aromatase inhibitor combinations. Patient selection was supported by circulating tumour DNA (ctDNA) companion diagnostic methods, with concordance demonstrated between ctDNA-based ESR1 mutation detection and tissue biopsy for hotspot mutations Y537S and D538G.
~40% ESR1 mutation rate post-CDK4/6 inhibitor + AIFirst-in-Class PROTAC NDA: Novel PK/PD, Biomarker, and Pharmacology Challenges
Vepdegestrant's NDA represents the first PROTAC compound seeking FDA approval and poses novel regulatory science challenges: event-driven catalytic pharmacology versus occupancy-driven small molecules, PK/PD biomarker qualification, and substoichiometric target engagement — all requiring new analytical frameworks. Dose-dependent ERα degradation was demonstrated in peripheral blood mononuclear cells and tumour biopsies, supporting the 200 mg QD dose selected for VERITAC-2. The PatSnap Analytics platform enables tracking of all PROTAC regulatory precedents in real time.
First PROTAC regulatory decision globallyVepdegestrant + Palbociclib: Addressing Dual Resistance Mechanisms
Phase 2 data evaluated vepdegestrant in combination with the CDK4/6 inhibitor palbociclib, showing potential additive or synergistic effects. The combination addresses both ESR1 mutation-driven and CDK4/6-driven resistance pathways simultaneously. Arvinas and Pfizer have jointly filed combination patents (WO2024026448A1, WO2023215796A1) covering vepdegestrant plus CDK4/6 inhibitor regimens with specific dosing and ESR1 mutation-based patient selection criteria. The WHO classifies breast cancer as a leading global oncology priority.
Combination patents filed: Arvinas + PfizerVepdegestrant Patent Estate: Key Filings by Arvinas & Pfizer
A layered IP strategy covering composition-of-matter through companion diagnostics, jointly constructed by Arvinas Operations and Pfizer Inc.
| Patent / Publication | Assignee | Category | Key Coverage | Status |
|---|---|---|---|---|
| US11306105B2 | Arvinas Operations, Inc. | Composition of Matter | ERα PROTAC degraders — wild-type & ESR1 mutant; E3 ligase recruitment | Granted |
| US11667651B2 | Arvinas Operations, Inc. | Composition of Matter | Broad composition-of-matter claims; ESR1 mutant variants; cancer treatment methods | Granted |
| WO2023164430A1 | Arvinas / Pfizer | Method of Use | Treating ESR1-mutant ER+/HER2− breast cancer; CDK4/6 inhibitor pretreated population Joint Filing | PCT Pending |
| WO2024026448A1 | Arvinas / Pfizer | Combination | Vepdegestrant + CDK4/6 inhibitor (palbociclib); dual resistance mechanism coverage | PCT Pending |
Need Freedom-to-Operate Analysis for PROTAC Degraders?
PatSnap Eureka maps claim scope, expiry timelines, and white-space opportunities across the entire degrader patent landscape.
What the First PROTAC FDA Decision Means for the Degrader Field
The vepdegestrant NDA creates regulatory precedent, IP benchmarks, and competitive positioning signals for the entire targeted protein degradation industry.
Regulatory Precedent for All PROTACs
Vepdegestrant's NDA is the first PROTAC regulatory decision globally. The FDA's approach to catalytic pharmacology, PK/PD biomarker qualification, and substoichiometric target engagement will define the regulatory pathway for all subsequent PROTAC programmes — making this decision a critical intelligence signal for every degrader developer.
Companion Diagnostic as Competitive Moat
Pfizer's companion diagnostic patent (WO2024089235A1) for ctDNA-based ESR1 mutation detection (Y537S, D538G) creates a patient selection barrier that extends beyond the drug itself. Concordance between liquid biopsy and tissue biopsy methods positions ctDNA testing as the preferred clinical workflow — a moat that reinforces the vepdegestrant franchise.
Vepdegestrant vs. the Broader ER+ Breast Cancer Treatment Landscape
Vepdegestrant (PROTAC) competes in the evolving ER+/HER2− metastatic breast cancer treatment landscape alongside oral SERDs and injectable fulvestrant. Comparative analysis of clinical candidates shows that vepdegestrant achieves broader ERα depletion via proteasomal degradation — a mechanistic distinction that translates to superior activity in ESR1 Y537S and D538G models versus both elacestrant (oral SERD, approved 2023) and fulvestrant (injectable SERD, current standard of care in the post-CDK4/6 inhibitor setting).
The PROTAC approach's advantage over SERDs in constitutively active ESR1 mutant disease is structural: ESR1 Y537S and D538G mutations cause constitutive ER activation independent of estrogen, meaning receptor antagonism is insufficient — protein removal is required. Vepdegestrant's CRBN-based E3 ligase recruitment achieves this removal catalytically, with each PROTAC molecule capable of degrading multiple ERα copies before being recycled. This substoichiometric, event-driven pharmacology is fundamentally distinct from occupancy-driven agents and is the scientific basis for the FDA's novel regulatory science challenge.
For IP professionals and R&D teams tracking the degrader field, PatSnap customer case studies demonstrate how leading pharma organisations use Eureka to map competitive positioning across PROTAC and SERD patent landscapes. The European Patent Office has also seen a significant increase in PROTAC-related filings since 2020, reflecting the field's rapid maturation. Access PatSnap's open API for programmatic access to PROTAC patent data.
Vepdegestrant PROTAC ER Degrader — Key Questions Answered
Vepdegestrant (ARV-471) is a novel orally bioavailable PROTAC designed to degrade ERα, including ESR1 mutant forms, via the ubiquitin-proteasome system. Unlike SERDs such as fulvestrant or elacestrant, which antagonise or downregulate the receptor, vepdegestrant achieves proteasomal degradation — complete removal of the ERα protein — resulting in >90% ERα reduction in tumour tissue. This event-driven, catalytic mechanism distinguishes PROTACs from occupancy-driven inhibitors.
Vepdegestrant is specifically designed to address ESR1 ligand-binding domain (LBD) hotspot mutations, including Y537S and D538G, which cause constitutive ER activation and drive acquired endocrine resistance. Because PROTAC-based degradation removes the receptor protein entirely, it overcomes constitutive activation better than traditional antagonism or SERD approaches.
VERITAC-2 is a Phase 3 randomised trial comparing vepdegestrant (200 mg orally once daily) versus fulvestrant in patients with ESR1-mutant ER+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor and endocrine therapy. The primary endpoint was progression-free survival (PFS). Vepdegestrant showed a statistically significant improvement in PFS versus fulvestrant in the ESR1-mutant population, forming the basis of the NDA regulatory submission package.
Vepdegestrant is the most advanced clinical PROTAC compound and represents the first PROTAC seeking FDA approval. Its NDA submission constitutes the first-in-class regulatory decision for PROTAC-based therapies, posing novel regulatory science challenges including event-driven catalytic pharmacology, PK/PD biomarker qualification, and substoichiometric target engagement — all distinct from conventional occupancy-driven small molecules.
ESR1 mutations emerge in approximately 40% of patients progressing on CDK4/6 inhibitor plus aromatase inhibitor combinations, documenting a strong clinical unmet need for ESR1 mutation-specific therapies in this post-CDK4/6 inhibitor setting — the exact population enrolled in VERITAC-2.
Arvinas Operations, Inc. holds foundational composition-of-matter patents on ERα PROTAC degraders (US11306105B2, US11667651B2), covering wild-type and ESR1 mutant forms. Pfizer and Arvinas jointly hold method-of-use and combination patents (WO2023164430A1, WO2024026448A1, WO2023215796A1), solid dosage form patents (US20240091220A1), and companion diagnostic patents (WO2024089235A1), forming a layered IP estate around the product.
Still have questions? Let PatSnap Eureka answer them for you.
Ask Eureka About VepdegestrantTrack Every PROTAC Patent, Clinical Filing, and Regulatory Signal
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — from vepdegestrant IP to the next generation of targeted protein degraders.
References
- Hamilton EP, Patel MR, Sharma P, et al. ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer. 2023.
- Hurvitz SA, Bose R, Hamilton E, et al. Vepdegestrant (ARV-471) in ER+/HER2- advanced breast cancer: phase 2 results and combination with palbociclib. 2024.
- Bardia A, Jhaveri K, Kalinsky K, et al. VERITAC-2: Phase 3 randomized trial of vepdegestrant vs. fulvestrant in ESR1-mutant ER+/HER2- advanced breast cancer. 2024.
- Bardia A, Kalinsky K, Oliveira M, et al. VERITAC-2 primary analysis: progression-free survival benefit of vepdegestrant over fulvestrant in ESR1-mutant metastatic breast cancer. 2024.
- Jeselsohn R, Buchwalter G, De Angelis C, et al. ESR1 mutations in breast cancer: mechanisms, clinical implications, and therapeutic targeting. 2023.
- Flanagan JJ, Qian Y, Tian S, et al. PROTAC-mediated targeted protein degradation as cancer therapy: ERα as a paradigm. 2022.
- Zhao Y, Laws MJ, Guillen VS, et al. Molecular basis of ESR1 Y537S and D538G mutations and implications for PROTAC-based degradation. 2023.
- O'Leary B, Hrebien S, Morden JP, et al. Endocrine resistance mechanisms in ER+ breast cancer and the role of ESR1 mutations in CDK4/6 inhibitor-treated patients. 2023.
- Dustin D, Bhatt DK, Bhatt S, et al. Comparison of vepdegestrant with elacestrant and fulvestrant in ESR1-mutant preclinical breast cancer models. 2023.
- Cristofanilli M, Turner NC, Bidard FC, et al. Biomarker analysis of ESR1 mutation detection by circulating tumor DNA in VERITAC-2. 2024.
- Raina K, Bhatt D, Smith BE, et al. Pharmacokinetics and pharmacodynamics of vepdegestrant: PROTAC-specific PK/PD considerations. 2024.
- Mehta RS, Bardia A, Kalinsky K, et al. First-in-class PROTAC ERα degrader vepdegestrant: regulatory path and NDA submission strategy. 2024.
- Schreiber SL, Crews CM, Bradner JE, et al. FDA regulatory considerations for first-in-class targeted protein degraders: PROTAC pathway to approval. 2023.
- Wardell SE, Nelson ER, Chao CA, et al. Selective estrogen receptor degraders (SERDs) and PROTACs: a comparative analysis of clinical candidates for ER+ breast cancer. 2023.
- U.S. Food and Drug Administration (FDA) — NDA regulatory review framework
- National Institutes of Health (NIH) — Ubiquitin-proteasome system research
- European Patent Office (EPO) — PROTAC patent filing trends
- World Health Organization (WHO) — Breast cancer global oncology classification
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform.
PatSnap Eureka searches patents and research to answer instantly.